Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115368 · ClinicalTrials.gov registry record · Phase 1
Study of GS-1219 in Participants With HIV-1
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT07115368 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 4 participants.
The verdict
NCT07115368, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-04 is to learn more about study drug GS-1219, safety, pharmacokinetics (PK) (how GS-1219 is absorbed, modified, distributed, and removed from the body of the participants), and antiviral activity in Participants With HIV-1.
Interventions
- DRUG BVY
- DRUG Standard of Care
- DRUG GS-1219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2025-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07115368
The ClinicalTrials.gov registry entry for NCT07115368 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BVY is the first listed.
NCT07115368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07115368 about?
NCT07115368 is a clinical study titled "Study of GS-1219 in Participants With HIV-1". This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-...
What is the current status of trial NCT07115368?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-08-11. Estimated completion is 2025-10-02.
What interventions are being tested in trial NCT07115368?
The interventions under investigation include: BVY (DRUG), Standard of Care (DRUG), GS-1219 (DRUG).
Who is sponsoring clinical trial NCT07115368?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.